Evorin pharma

Evorin pharma http://evorin.com/ Professional treatment with the most scientifically advanced solutions

Evorin pharma is a leading health services and innovation company on a mission to continuously generate groundbreaking ideas in the name of Health and beauty. We have years of experience in developing innovative products and unique treatment methods and we promise to continue this tradition of excellence. Building a unique portfolio of Health and beauty and related brands, striving to surpass competitors in quality, innovation, and value, and elevating Evorin's image to become the world's most trusted Pharmaceutical and Cosme-ceutical company.

Alzheimer's risk calculator could spot danger years before symptoms beginMayo Clinic researchers have developed a new to...
13/11/2025

Alzheimer's risk calculator could spot danger years before symptoms begin

Mayo Clinic researchers have developed a new tool that can estimate a person's risk of developing memory and thinking problems associated with Alzheimer's disease years before symptoms appear.

The research, published in The Lancet Neurology, builds on decades of data from the Mayo Clinic Study of Aging—one of the world's most comprehensive population-based studies of brain health.

The study found that women have a higher lifetime risk than men of developing dementia and mild cognitive impairment (MCI), a transitional stage between healthy aging and dementia that often affects quality of life but still allows people to live independently. Men and women with the common genetic variant, APOE ε4, also have a higher lifetime risk.

Predicting Alzheimer's disease
Alzheimer's disease is marked by two key proteins in the brain: amyloid, which forms plaques, and tau, which forms tangles. Drugs recently approved by the Food and Drug Administration remove amyloid from the brain and can slow the rate of disease progression for people with MCI or mild dementia.

"What's exciting now is that we're looking even earlier—before symptoms begin—to see if we can predict who might be at greatest risk of developing cognitive problems in the future," says Clifford Jack, Jr., M.D., radiologist and lead author of the study.

The new prediction model combined several factors, including age, s*x, genetic risk as associated with APOE genotype and brain amyloid levels detected on PET scans. Using the data, researchers can calculate an individual's likelihood of developing MCI or dementia within 10 years or over the predicted lifetime. Of all the predictors evaluated, the brain amyloid levels detected on PET scans was the predictor with the largest effect for lifetime risk of both MCI and dementia.

"This kind of risk estimate could eventually help people and their doctors decide when to begin therapy or make lifestyle changes that may delay the onset of symptoms. It's similar to how cholesterol levels help predict heart attack risk," says Ronald Petersen, M.D., Ph.D., neurologist and director of the Mayo Clinic Study of Aging, who is a co-author of the study.

The research stands apart because it draws from the Mayo Clinic Study of Aging, a long-running effort in Olmsted County, Minnesota, that tracks thousands of residents over time. The analysis for this study included data from 5,858 participants. Unlike most studies, Mayo researchers are able to continue following participants even after they stop actively taking part, using medical record data—ensuring nearly complete information about who develops cognitive decline or dementia.

"This gives us a uniquely accurate picture of how Alzheimer's unfolds in the community," says Terry Therneau, Ph.D., who led the statistical analysis and is the senior author of the study. "We found that the incident rate of dementia was two times greater among the people who dropped out of the study than those who continued to participate."

The study elevates the significance of MCI, which is the stage targeted by current Alzheimer's drugs that slow but do not stop progression.

While the new tool is currently a research instrument, it represents a major step toward more personalized care. Future versions may incorporate blood-based biomarkers, which could make testing more accessible.

"Ultimately, our goal is to give people more time—time to plan, to act and to live well before memory problems take hold," says Dr. Petersen.

Healthcare Trends That Will Transform Medicine In 2025Healthcare has evolved dramatically in recent years, with technolo...
30/10/2025

Healthcare Trends That Will Transform Medicine In 2025

Healthcare has evolved dramatically in recent years, with technology driving countless new opportunities, just as demographic and societal factors have created new challenges.

This trajectory will continue into 2025, as advancements in AI, remote medicine, and biotechnology continue to reshape healthcare planning and delivery.

From a big-picture perspective, we’ll continue to see a shift towards predictive measures as systems adapt to cope with aging demographics, population booms in the developing world and financial challenges caused by economic uncertainty.

So, here are what I believe will be the most important and impactful trends in healthcare over the next year.

The Personalized Healthcare Revolution
In 2025, personalized healthcare means more than just precision medicine – it’s about tapping into the power of AI and data to address every aspect of a patient’s unique needs. Think tailored wellness plans and communication strategies aimed at encouraging hard-to-reach demographic groups to engage with healthcare providers. This personal touch will help push health provision away from reactive to preventative measures - reducing the burden to society caused by rising healthcare costs while also improving patient outcomes – a win-win scenario.

Future-Proofing Healthcare
AI will continue to transform the way that healthcare systems plan for and respond to large-scale challenges, ranging from future pandemics to health crises caused by war, famine and climate change. In 2025, decision-makers will have more data and tools at their fingertips than ever before, and it will all be essential when it comes to understanding global trends impacting human health. This will include addressing the needs of aging populations in developed countries, and the growing healthcare demands of growing populations in developing parts of the world.

Technology In Mental Wellness
A new generation of technological solutions will revolutionize the delivery of mental healthcare services. This will include virtual healthcare sessions delivered remotely in VR or AR environment by human therapists. We will also see the growing use of chatbots that can provide instantaneous 24/7 support. These technologies will help mental healthcare service providers overcome a number of challenges, including availability of resources, and stigma sometimes associated with seeking help for mental health problems. As this field of healthcare increasingly becomes a priority for service providers, these technological solutions will enable greater accessibility and more timely interventions.

Wearables 2.0 – BCIs And Implants
Implantable devices such as brain-computer interfaces (BCIs) represent the next generation of wearable health-tech devices. Even if you’re not quite ready to start plugging chips into your cerebral cortex, you can expect to see growing discussion, excitement and hype around the topic in 2025. From chronic pain management to epilepsy and paralysis, this technology is showing promise for solving a number of healthcare challenges that negatively impact the lives of millions of people. However it also raises many ethical questions – such as who owns the data generated by our brains?

Genomics – Decoding The Secrets Of Life?
Genomics and gene editing are perhaps some of the most exciting and also ethically challenging areas of healthcare innovation. Technologies like CRISPR are increasingly moving from laboratory to real-world clinical application, enabling the development of targeted treatments for many genetic conditions, such as cystic fibrosis, Huntington’s disease and muscular dystrophy that were once thought incurable. In 2025 we will see continuing research into its implications for cancer and cardiovascular disease, thanks to the ability of this breakthrough technology to treat these life-threatening conditions at a molecular level.

The Health Data Dilemma
The explosion in the volume of health data – from our medical records to genomic information, and data collected from wearables – is leading to rapid advances in the science of healthcare. However it’s a double-edged sword – the more organizations and agencies we allow to access our highly valuable and sensitive information, the greater the risk of it being stolen or misused. Our health data is a hugely valuable target for cybercriminals and many problems could be caused by it falling into the wrong hands – from identity theft today, to future issues that can’t even be foreseen tomorrow. The financial risk alone is enough to prompt the healthcare industry to take action - according to the WEF, it is the sector that suffers most heavily from the impact of data breaches, with the average breach costing close to $11 million. Developing strategies for securing our information and protecting society from this looming threat will be a critical priority for the healthcare industry in 2025.

Solving Healthcare’s Tech Skills Crisis
All of this potential for game-changing, AI-driven, precision-targeted diagnoses and drug discovery will be thwarted if there aren’t enough skilled people to make it happen. A recent survey into digital transformation challenges in healthcare found that a lack of specific skills and talent are the biggest obstacles to benefitting from opportunities created by new technology. In 2025, we’ll see the healthcare industry and health service providers attempting to tackle this by investing in training, reskilling and partnering with the tech industry. All of this will be essential if the huge benefits of AI and biotechnology are to be realized.

In 2025, healthcare stands at a pivotal moment of transformation, where technological innovation offers unprecedented opportunities to improve patient outcomes and healthcare delivery. However, the success of these advancements – from personalized medicine to brain-computer interfaces – hinges on our ability to address critical challenges around data security, ethical considerations, and the growing skills gap. Healthcare providers, technology companies, and educational institutions must collaborate to build a workforce capable of implementing these innovations safely and effectively. The future of healthcare isn't just about developing new technologies – it's about creating a sustainable ecosystem where innovation, security, and human expertise work in harmony to deliver better healthcare for all.

Parent opioid prescriptions linked to teen and young adult opioid useIf a parent has persistent opioid prescriptions, th...
23/10/2025

Parent opioid prescriptions linked to teen and
young adult opioid use

If a parent has persistent opioid
prescriptions, their adolescent or young adult
offspring has more than double the risk of
persistent opioid use, according to a new
study published in PLOS Medicine by Anna
Marcuzzi of the Norwegian University of
Science and Technology, Norway, and
colleagues.

The prescription of strong analgesics such as
opioids is not recommended for young people.
However, despite potential adverse long-term
consequences, opioids are often prescribed for
non-malignant pain in this population.

In a new study, researchers have analyzed data
from 21,470 adolescents and young adults aged
13–29 years who participated in the
population-based Young-HUNT or HUNT Study in
Norway in 2006-2008 or 2017-2019. Each
participant was linked with at least one
parent who also participated in the HUNT
study, and opioid prescription data were
obtained from the Norwegian Prescription
Database.

They found that 24.4% of young people had at
least one opioid prescription during the
seven-year follow-up period, while 1.3% had
persistent opioid prescriptions, defined as
prescriptions in at least three out of four
quarters of a year.

When a mother had persistent opioid
prescriptions over a five-year period (two
years before and three years after offspring
participation), their offspring had 2.60 times
the risk of persistent opioid use compared to
those whose mothers had no prescriptions. When
a father had persistent opioid prescriptions,
their offspring had 2.37 times the risk of
persistent opioid use.

The association was also present but weaker
for non-persistent opioid prescription—
offspring whose mothers had two or more
prescriptions had 1.34 times the risk of
receiving any opioid prescription, while those
whose fathers had two or more prescriptions
had 1.19 times the risk, compared to offspring
whose parents had no prescriptions. There was
no clear evidence that parental chronic
musculoskeletal pain status influenced these
associations.

The authors note that because parental opioid
prescriptions were measured both before and
after offspring HUNT participation, some
parental opioid prescriptions could have begun
after offspring opioid use. However, they
conclude that there is an association between
parental and offspring opioid prescriptions.

"The study findings suggest that family-based
strategies should be considered when managing
pain conditions in adolescents and young
adults to avoid potentially unnecessary opioid
use," they say.

The researchers add, "Despite restrictive
opioid policies, one in four adolescents and
young adults received an opioid prescription
during the seven years of follow-up.

"Adolescents whose parents had two or more
opioid prescriptions had a more than two-fold
higher risk of persistent opioid use (i.e.,
multiple prescriptions in a year) than if the
parents had no opioid prescriptions."

Top 5 AI-driven medical innovations in the United StatesThe integration of AI in the healthcare industry could yield rem...
16/10/2025

Top 5 AI-driven medical innovations in the
United States

The integration of AI in the healthcare
industry could yield remarkable savings for
the United States, projected at a staggering
US$360 billion. This insight emerged in a
report by researchers from McKinsey and
Harvard. Artificial Intelligence (AI) and
machine learning (ML) are revolutionising
medical devices, drug development, diagnosis
and treatment. By automating tasks, they
complement healthcare practitioners’ work,
promising to advance decision-making, cut
costs and enhance the patient experience.

AI-powered medical devices
In 2022, the United States Food and Drug
Administration (FDA) authorised 91 medical
devices equipped with AI or ML capabilities.
This category covers important algorithms and
sophisticated machine-learning tools. One such
example is an atrial fibrillation history
feature incorporated into the Apple Watch.
Another tool designed by Aidoc, a radiology AI
company, received FDA clearance for its AI-
powered feature, designed to detect collapsed
lungs on X-ray images. This streamlines the
diagnostic process and allows physicians to
prioritise critical images.

AI-generated digital biomarkers
The fusion of physiological data with
lifestyle and environmental factors is paving
the way for deep phenotyping. Coupled with
genomics, this is set to take healthcare to
new heights. Bloomer Tech is combining
cutting-edge fabric technology with ML to
transform clothes, for example, women's bras,
into wearable medical devices. AI's role in
generating digital biomarkers promises
transformative impacts, especially for
diseases that disproportionately affect women.
Bloomer Tech’s focus lies in the
cardiovascular system in women, given the
challenges in diagnostics and treatment. The
company aims to shift from limited biomarkers
analysed in labs to AI-driven insights taken
from clothing. This shift could revolutionise
healthcare by enabling proactive and pre-
emptive care.

AI in clinical decision support
AI-based Clinical Decision Support Software
(CDSS) is another innovation with the
potential to transform patient care by
analysing historical, current and incoming
patient data. The software can identify safety
concerns, errors and spot opportunities for
enhancing care pathways. AI CDSS could improve
the diagnosis, treatment and prognosis of
specific medical conditions. The FDA issued
new guidance stating certain AI tools should
be regulated as medical devices, in particular
those predicting sepsis, patient
deterioration, and heart failure. This change
reflects the growing use of AI and ML, which
can improve performance through learning from
experience.

Drug development revolutionised by AI
AI can accelerate the development of new drugs
and the technology is reshaping the process,
driving significant improvements. Drug
development takes 12 to 18 years, costing US$2
to US$3 billion, with only 10 per cent
approval. AI can speed up R&D, cut costs and
boost the chances of drug approval. COVID-19
accelerated AI adoption in drug discovery, a
turning point for the pharmaceutical industry.
In February 2020, Eli Lilly's Olumiant was
identified by UK-based start-up BenevolentAI
as a potential COVID-19 treatment, receiving
FDA Emergency Use Authorisation in just three
days.

AI's impact on value-based care
Integrating AI into value-based care models is
another ground-breaking innovation. AI has
enormous potential for enhancing operational
efficiency and patient outcomes, creating
shared savings opportunities. The healthcare
sector is realising the advantages of using AI
to analyse health trends and deliver superior,
value-based care. David Friede, Vice President
of Strategic Partnerships for the DrOwl app,
highlights one example where AI creates a
digital twin of a patient, enabling the
exploration of treatments and outcomes. This
approach enhances the patient journey and
overall healthcare experience.

Related: The current status and future
potential of AI in medical imaging

As these AI-powered advancements unfold, the
influence of AI in healthcare is nothing short
of revolutionary. Advancements promise to
reshape healthcare, enabling a future where
innovation, precision and patient-centric care
are paramount. AI is expected to strengthen,
not replace, human judgement leading to
quicker, more informed decisions, lower costs,
and ultimately enhanced patient care.

AI MRI empowers increased throughput and exceptional image quality at PotsdamAfter acquiring Philips SmartSpeed, Dr. Tob...
04/10/2025

AI MRI empowers increased throughput and exceptional image quality at Potsdam

After acquiring Philips SmartSpeed, Dr. Tobias Schr?ter was astonished at the great potential of this AI MRI technology. It sets the stage for rapid, high quality MRI exams in his practice. He points out that across all anatomies, he discovers that shorter scan times and exceptional detail means faster, more confident diagnoses. Patient throughput has improved by about 20 percent.

At-a-glance:
Using SmartSpeed with AI showed Dr. Tobias Schr?ter that sharp, high-resolution images in short times means faster, more confident diagnoses.
It allowed the practice to improve its patient throughput by about 20 percent.
Motion artifacts no longer play a major role as patients’ stay shorter in the magnet and SmartSpeed reduces motion artifacts better than before.
Use of 3D imaging for all joints helps visualize very small structures. MPRs of tendons, ligaments, cartilage with this high-resolution help see the extent of possible injuries.

Making a difference with fast, powerful technology
Dr. Tobias Schr?ter, MD, has been a radiologist since 2000. After running a 24/7 radiology practice for 16 years, he took over MRT-Praxis Potsdam, specializing in MRI diagnostics. “After the takeover, I completely redesigned the premises and exchanged the older MRI machine for a 1.5T Philips Ingenia Ambition S with sealed magnet.”

Recently, the MRI Practice in Potsdam acquired AI-based Philips SmartSpeed of which Dr. Schr?ter has found that it makes a significant difference. “We had already been using Compressed SENSE from Philips to accelerate our cartesian scans and increase throughput. SmartSpeed now allows us to further reduce scan times and artificial intelligence (AI) makes the image quality even better compared to images we acquired using Compressed SENSE.”

Dr. Schr?ter now uses SmartSpeed for 2D and 3D sequences in all anatomies. “I am astonished at the great potential of SmartSpeed, especially because 3D imaging in MSK is becoming feasible now. I can get very good image quality in very short scan time.” He also uses SmartSpeed for patients that cannot hold still, without worrying about needing re-scans. And it can also be used for patients with implants.

“Besides the fast scanning, we now have the advantage of fast image reconstruction, so that we can already look at images while the scanning is still ongoing.”

Higher patient throughput
MRT-Praxis Potsdam mostly focuses on neuro imaging and musculoskeletal examinations. They also perform prostate examinations, and occasionally some abdominal MRI.

“Philips SmartSpeed really helps us scan more patients per day,” Dr. Schr?ter says. “We achieve higher throughput and better productivity without compromising on image quality. We used to scan 32 to 35 patients per day, but now with SmartSpeed we can perform significantly more examinations in less time. We went from 160 to 170 exams per week before SmartSpeed to up to 200 per week, or about 40 patients per day.

“The short MRI scan times that we realize with SmartSpeed also provide better comfort for all our patients. Not everyone is comfortable lying in the scanner. Even normal, healthy individuals often cannot lie still for that long, which may lead to motion artifacts. So, being able to image faster is an obvious benefit. Our average examination time is now about 10 minutes. Only a few of our exams need more than 20 minutes.”

Faster scans, faster diagnoses [1], high productivity
“Thanks to SmartSpeed, we are able to perform examinations extremely quickly. We can carry out most examinations in under ten minutes. Our MRI exam of the knee only takes six minutes. The shorter time makes it easier for patients to lay still, which helps prevent motion artifacts.

Then, because the computing capacity is so large, we have the images immediately available on the large screen. Higher resolution is very valuable. From the high-resolution 3D sequences, excellent multiplanar reconstruction can be obtained. This makes it easier and faster for us to diagnose and create reports. And while the patient is still lying in the magnet, we can already view the images and make a diagnosis. When the patient comes out, I can immediately ask whether what I see corresponds to the symptoms.”

Dr. Schr?ter also highlights their step forward in MRI of the prostate. “In prostate exams we have saved almost 50 percent of time. We used to need about 35 minutes for an MRI exam of the prostate and now we can do it in just 18 minutes with a significantly higher resolution and higher image quality.”

According to Dr. Schr?ter the advances that come with SmartSpeed enable them to more frequently use metal artifact suppression sequences, such as O-MAR, for imaging joints with prostheses. This sequence can now be acquired in the relatively short time of three minutes and Dr. Schr?ter observes significant progress in recognizing anatomy in the vicinity of the prostheses.

SmartSpeed brought options for motion-free imaging, so motion artifacts no longer play a major role like before. Dr. Schr?ter says the team sees fewer repeat scans when using SmartSpeed, “Firstly, because patients’ time in the magnet is shorter, and secondly because SmartSpeed MotionFree reduces motion artifacts better than before.”

How SmartSpeed helps
According to Dr. Schr?ter MRI is a powerful imaging modality, but for producing images with high resolution and excellent detail, a long scan time is often required. In addition, motion artifacts can be a problem, as remaining motionless throughout the exam is difficult for many patients.

“Now, with SmartSpeed, we can achieve better results – high image resolution and razor-sharp images – in the shortest possible time. That is an advantage both for the patient and for us: the patient gets out of the scanner faster and diagnosing and reporting is easier for us.”

“I can use SmartSpeed on patients with implants and for patients that cannot hold still, without worrying about re-scans due to motion. I am astonished by the great potential of SmartSpeed. I can get very good image quality in very short scan time, and 3D imaging in MSK is now feasible for us.”

A leap in MSK imaging thanks to SmartSpeed
Previously, the practice wasn’t able to use 3D imaging on all joints, because the time required was too long, and on some joints it was simply not possible to achieve a good quality image, Dr. Schr?ter says. “Now, with SmartSpeed we consistently use 3D imaging for all joints and can thus discover the smallest changes, for example in the cartilage. And that, of course, helps us in making a detailed diagnosis.”

Dr. Schr?ter says their MSK images show high contrast and extremely high quality. He mentions the menisci as an example. “We use a 3D proton density weighted fatsat sequence, thickness is 0.3 mm and scan time 3 minutes. The MPRs show an unbelievable resolution. Very small tears and even fraying of the tip of the meniscus become visible, which is normally only possible in arthroscopic surgery.

When imaging the small joints of the fingers and the thumb we achieve extraordinary quality. Using SmartSpeed we succeed in displaying even very small structures anatomically correct, enabling us to see the extent of possible injuries. Tendons and ligaments appear with higher resolution so we can better see the injury pattern and describe and delimit it.

Our referring physicians are fascinated by the extraordinary quality and high level of detail of the images. Patients are happy that the examination does not take too long. We hear from patients that it took a lot less time than they expected. This is especially important when scanning patients who are very uncomfortable in the MRI environment.”

Improving diagnostic confidence across the board at MRT-Praxis Potsdam
Dr. Schr?ter points out that a more confident diagnosis requires high-quality images with more diagnostic information. “Philips SmartSpeed provided that to us. AI denoises the clinical images without losing any important data, resulting in high-resolution images. It keeps all the information we need and makes the images better.

We can apply SmartSpeed to almost all sequences. That is a big step forward! We use it for example in 3D imaging and in diffusion-weighted imaging, to dramatically reduce scan time or increase image resolution, which is quite useful.

There are small lesions that we would certainly have seen without SmartSpeed, however it would have taken us longer to properly diagnose. In 3D MSK images with extremely high resolution, we uncover the finest anatomical structures and can thus report very detailed findings.”

Helium-free operation helps saving costs
When Dr. Schr?ter initially planned to replace the old MRI system, he learned that safety requirements for the quench system had become so strict that the existing vent pipe could no longer be used and costs for updating it in the heritage-protected building were excessive.

Choosing the Philips Ambition S with its BlueSeal magnet allowed Dr. Schr?ter to avoid the expensive conversion, as this magnet does not require a vent pipe, because the helium is permanently enclosed within the sealed magnet. The seven-liter helium content of the BlueSeal magnet is also significantly lower than the roughly 1,500 liters of other Philips magnets.

“With the BlueSeal magnet we don't need to concern ourselves with helium anymore. Refills are not needed, so there’s no time or cost wasted with that. Sustainability was also an important aspect for me when deciding on BlueSeal. Helium is a resource that is not infinitely available on earth, that's why I think it's good that we have a closed system that only includes seven liters.

As a radiologist I can't see any difference between images from a sealed system and a system that requires regular helium refill. The image quality and the handling are virtually the same.”

Effects of a patient-friendly atmosphere
“In our MRI room we have the Ambient Experience lighting and In-bore experience, which enable us to create a feel-good atmosphere for our patients,” says Dr. Schr?ter. “They feel more comfortable with this experience than in MRI machines without. Our patients love it. It helps many to successfully tolerate the examination. When inside the bore, patients can see the remaining scan time and breath hold guidance on the display. This is very popular. It improves patient engagement and ultimately image quality.

Many patients tell us that if they had known how nice it was in our device, they wouldn't have been afraid of the exam. Patients often say that they will recommend us to others if they ever need an MRI.

Thanks to image quality and a relaxing environment we have been able to scan a higher number of patients. I can emphasize that with the Ambition system, our patient throughput and exam scope have grown.”

Large screen and easy operation
Philips SmartSpeed is available via MR Workspace, the large-screen operator console that empowers the technologist with integrated AI protocol selection.

“The big 27-inch 4K high resolution screen makes a total difference. It shows the large planning images with much higher resolution than we were used to. Anatomic landmarks can be more easily identified, which advances the process. Now it is much easier and faster to plan the new sequences and it’s easier for us to find lesions,” says Dr. Schr?ter.

“MR Workspace is a tool to operate the system more seamlessly. The user interface is designed in a very advanced way. Operation is intuitive. Many actions can be executed via drag and drop. It is really easy to use and self-explanatory. There are small features and tools that improve the work significantly. For example, being able to copy the geometry of one sequence to the next, without having to make any major adjustments.

We also use the new Day manager. During an ongoing examination it allows us to load and adjust the planned examinations for upcoming patients at the same time.”

Powerful GPU rapidly provides images and reconstruction on large screen
Another important part of MR Workspace is the graphics processing unit (GPU), which allows on-the-fly reconstruction times for images acquired with SmartSpeed. “In addition to seeing razor-sharp images on the large 4K monitor, we also have better and faster reconstruction of the images. Using this extremely high resolution, we sometimes have sequences with up to 800 individual images. The GPU then manages to convert them in a matter of seconds into multiplanar reconstructions. Very impressive.”

Staff learning curve
“We’ve received great application training from Phillips”, Dr. Schr?ter says. “My highly motivated technologists were able to recognize the advantages of SmartSpeed in a very short time. Simultaneously they were also getting used to the new MR Workspace, which is completely different from the previous operating console. However, the new workspace is modern and very easy to use. We can simply select SmartSpeed from the menu.

When Compressed SENSE protocols are available, only one click is needed to convert to a SmartSpeed sequence. And we can adjust the denoising levels depending on our needs: strong, medium or weak and achieve the best level for our practice. It makes work easier overall.”

Everybody wins
Dr. Schr?ter believes SmartSpeed is really a step forward. “It is almost incomprehensible that scanning can be so fast. And the images are brilliant. I'm excited. For all of our examinations the scanning time was drastically shortened – particularly the switch to 3D sequences makes a difference. Our practice is now able to use some sequences that were hardly used before because of their long scan time.

SmartSpeed is a real game changer. The decisive factor is that we can now achieve this speed and this high resolution. And I can only say yes to the question on consistency of the picture quality. We can always produce brilliant images with SmartSpeed, so it is not necessary to repeat sequences.

Faster scanning means less possibility for motion artifacts, less rescans and a much better result. We gain more confidence during reporting, so patients are getting a much better diagnosis. Everybody wins.”

Address

UK Address: PLUM TREE HOUSE/OLD VICARAGE Lane SWINDON/UNITED KINGDOM/SN3 4SH : Dubai Address:Office No. 2108, Jumeirah Bay Tower/Dubai/
Dubai

Opening Hours

Monday 08:00 - 18:00
Tuesday 08:00 - 18:00
Wednesday 08:00 - 18:00
Thursday 08:00 - 18:00
Sunday 08:00 - 18:00

Alerts

Be the first to know and let us send you an email when Evorin pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Evorin pharma:

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category